Wednesday, November 18, 2026 Evidence-led medical research news
The First Cohort
Medical research, with the receipts

obesity

29 stories · Page 2 of 2

Metabolic & Weight

Same Calories, Different Wiring: Why Fructose Leaves Your Hunger Neurons Running

Glucose flips off the brain cells that drive hunger. Fructose barely nudges them, and the corn-syrup blend in your soda quiets them even better, which is exactly why it's so easy to keep drinking.

Metabolic & Weight

The Obesity 'Revolution' Everyone's Promising Comes From People Who'd Cash In On It

A new commentary says the GLP-1 era is just the prelude to a bigger obesity "revolution." The authors have direct financial stakes in what comes next, and the celebrated new pill loses less weight than the shot.

Metabolic & Weight

The Oral GLP-1 Race Just Got a Third Serious Contender, and Its Curve Was Still Climbing

Structure Therapeutics' once-daily oral GLP-1 aleniglipron hit 11.3 percent placebo-adjusted weight loss at 36 weeks and kept climbing in the open label. The catch: oral semaglutide and orforglipron already cleared the FDA.

Metabolic & Weight

Retatrutide's Triple-Receptor Triumph Came With a One-in-Five Skin-Sensation Signal Nobody Wanted to Linger On

Eli Lilly's investigational retatrutide hit bariatric-surgery-level weight loss at ADA 2026. The highest-dose arm of TRIUMPH-4 also saw 20.9% of patients report abnormal skin sensations, and a small cardiac imbalance turned up in the type-2 trial. Both got far less stage time than the headline numbe

Metabolic & Weight

Lilly's triple agonist hit 30% weight loss. The glucagon bet is why.

Lilly's triple agonist hit nearly 30% weight loss at 104 weeks at ADA 2026. The glucagon bet is what makes retatrutide different from semaglutide and Mounjaro, and it's what makes the open safety signals different too.